Authors


Frank Saia

Latest:

AI and Social Listening: Myths vs. Facts

What’s all the mystery about?



Meerim Almazbek

Latest:

The Diversity Mindset: Benefits of Tapping External Sources

Seeking opportunities to be more inclusive can help pharma companies gain a deeper understanding of key opinion leader and patient perspectives and build diversity into the entire product journey.


Dan Rizzo

Latest:

Why Medical Engagement With Key Opinion Leaders Drives Treatment Adoption: Q&A with Dan Rizzo, global head of Veeva business consulting

With treatments becoming more complex, the life sciences industry needs more professionals with specialized knowledge.



Vish Khanna

Latest:

Scale Down Before Scaling Up: Digital Innovation in a Highly Regulated Industry

The highly-regulated pharmaceutical industry poses serious challenges that can derail digital health programs. But, there are solutions.


Allen Davidoff

Latest:

Combining Regulatory Pathways to Optimize Development Efficiency

Multiple regulatory pathways exist during the drug development process.


Nina Levin

Latest:

MSL Teams Need to Digitize, or Face Being Left Behind

Medical science liaisons (MSL) in the pharma industry were already at their limit pre-COVID. The challenge for MSLs is to identify the most efficient way to upskill their teams and add digital competencies without overloading them.


Geralyn Ritter

Latest:

Sustainability and Progress Continue to Make Headlines in 2024

Recognition of the business case for ESG in pharma is soaring.


Cassie Stox

Latest:

Measuring Omnichannel Efforts in Medical Affairs

A five-step pilot approach to effective measurement of medical affairs omnichannel efforts.



Komodo Health

Latest:

The State of Mining Data Insights in the Life Sciences Industry – 2024 (April 2024)

A recent industry-wide survey reveals disconnects and unmet needs pertaining to real-world patient data and analytics that can impact business decision making.


Philipp Hofmann, MD

Latest:

Current Status of Biosimilars and Their Impact on Pharmacovigilance

As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.



Autumn Vaupel

Latest:

Sustaining Pace With Contingent Workers

Pandemic workforce trends continue to create challenges for pharma.



The Whyse

Latest:

Word to the Whyse presents: The Science of Engagement

*** Time and Date: Tuesday, November 17 I 11:00 am – 2:30 pm EST *** *** On-demand available after final airing until Nov. 17, 2021***


Michael Lynch

Latest:

Overcoming HCP Engagement Fatigue with Data-Driven Insights

With a single source of data united under a single privacy policy, pharma marketers are equipped to plan, engage, measure, and optimize a targeted digital marketing model.


Julia Libunao

Latest:

Why Program Management is the Key to Success for Life Science Companies

Delivering value with enterprise program management.


Phreesia

Latest:

Trends to Watch in Patient-first Pharma Marketing

As healthcare increasingly shifts to digital, new pharma marketing and patient engagement trends are emerging at the forefront of care. In this podcast, Phreesia Life Sciences and Pharmaceutical Executive discuss how technology is changing healthcare consumers’ expectations and helping to create more personalized experiences focused on connecting the right patients to the right content, care and resources.


Leanne Larson

Latest:

Industry Game Changer: RWE Impacts on Drug Development

COVID may have given real-world evidence the boost it needed to become routine, especially in areas that demand research innovation and advancement.


Smita Pillai

Latest:

The Harms of ‘Helicopter Research’ in the Life Sciences

How pharma companies can make justice and integrity a priority.



Michael Howley PA-C, MBA, PhD

Latest:

Data Intermediaries/Software Can Speed the Usage of Real-World Data

Survey taken by pharma and CRO executives evaluates how effectively various programs convert RWD into usable data.


Sarah Averill Lott

Latest:

Open Science and Digital Health: A Brighter Future for Parkinson’s Disease

Collaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.



Shiying He

Latest:

China’s 2022 NRDL Readout

Despite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.


Scott Snyder

Latest:

Pharmatizing AI

Using the 3 Rs to guide AI transformation in Pharma.


Doron Aspitz

Latest:

Harnessing AI for Pharma Sales

Artificial intelligence is steadily becoming a game changer for the pharma industry, particularly in commercialization activities, such as sales and marketing—and efforts to help highly sought treatments reach the right patients.


Janardan Prasad

Latest:

How A Self-Service Data Platform for Life Sciences Analytics Can Fast-Track Drug Readiness

Owning a self-service data platform allows emerging pharma and biotech companies to accelerate past data engineering intricacies and focus on ad-hoc analytics to discern how their data can help them meet objectives for clinical operations, medical affairs, and commercial teams.